Rajeev M. Shah - Jun 17, 2021 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Role
Director
Signature
/s/ Mary Reumuth, Attorney-in-Fact
Stock symbol
KALA
Transactions as of
Jun 17, 2021
Transactions value $
$0
Form type
4
Date filed
6/21/2021, 05:31 PM
Previous filing
Jun 21, 2021
Next filing
Jun 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALA Common Stock Award $0 +20K $0.00 20K Jun 17, 2021 Direct F1, F2
holding KALA Common Stock 10.9M Jun 17, 2021 See Footnote F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the RSUs on the earlier of (i) June 17, 2022 or (ii) the date of the first annual meeting following June 17, 2021.
F2 Includes 20,000 unvested RSUs.
F3 Includes 20,000 shares of the Issuer's common stock that the reporting person turned over to the adviser (as defined below) following the settlement of RSUs.
F4 Under the reporting person's arrangement with RA Capital Management, L.P. (the "adviser"), the Reporting Person holds the RSUs for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The reporting person is obligated to turn over to the adviser any stock received from the settlement of the RSUs, which will offset advisory fees owed by the Fund to the Adviser. The reporting person therefore disclaims beneficial ownership of the RSUs and underlying common stock.
F5 The reporting person disclaims beneficial ownership of the reported securities held by the Fund for purposes of Rule 16a-1(a)(2) except to the extent of his pecuniary interest therein.